13 February 2019: The Global Cystic Fibrosis (CF) Therapeutics Market is expected to be valued at USD 13.9 billion with CAGR of 16.7% over the forecast period. Cystic fibrosis (CF) is a severe disease that causes overall damage to lungs, digestive systems and other organs in the body. In this state, CF affects the cells that are responsible for sweat, mucus digestive and fluid juices. These juices are normally thin and slippery but patients suffering from cystic fibrosis experience thick blockage in lungs and other organs, as this affects the cells that regulate digestive and fluid juices causing them to become an obstacle rather than carriers. The cells instead of acting as a lubricant become sticky and thick, thus blocking up lungs, pancreas and other organs in the body. Medically this disease is termed as mucoviscidosis.
Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market/request-sample
The major driving factors of this market rely significantly on extensive R&D. As the ongoing R&D activities have boosted the CF therapeutics market and witnesses a lucrative growth in the upcoming years. The other driving factors like awareness for cystic fibrosis therapy, technological advancements in R&D attribute to the success of market growth. However, high costs of treatment and R&D, entangled pathophysiology, rising rate in genetic mutation are some factors that may cause to hinder the market growth. On the basis of therapeutics, the global market is segmented into pulmozyme, TOBI, kalydeco, Cayston, Arikace, Aeroquin and others.
Cystic Fibrosis Trans membrane Conductance Regulators (CFTR) modulators treat the root cause of disease rather than symptoms, resulting in improving the lives of patients. Kalydeco is the first CFTR modulator to enter the market and had a large impact on the value of market though it treated a small proportion of CF patients. Pricing will be premium for CFTR modulators due to the therapeutic benefits. Symptomatic therapies will continue to be a necessary part in conjunction with CFTR modules. Comparatively, the antibiotics segment is expected to gain second importance owing to the competitiveness and novel market entrants.
https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market
A multi-resistant superbug infection that can prove fatal for patients suffering from cystic fibrosis (CF) has spread globally and is becoming viral, according to the British researchers. Moreover, it has not only gone viral but is evolved and capable to jump from patient to patient, according Andres Floto, a Cambridge University professor. Adding further, he said that as the superbug has become resistant to various antibiotics; it is also difficult to treat it successfully. As a part of treatment infected patients may need more than a year of treatment with a combination of strong antibiotics and the ratio of cure is one in three.
The market is segmented on the basis of geography which includes North America, Europe, Asia-Pacific, Middle-east and Africa. The European region dominates the global market scenario and is considered as the most fertile market which is also followed by North America. Asia-pacific regions are considered to be the least important market owing to less prevalence of the disorder. The key players include Novartis International AG, Chiesi Farmaceutici SpA, Vertex Pharmaceuticals, Genentech, Inc., and Gilead Sciences, Inc. Vertex Pharmaceuticals is the developer of kalydeco and expected to be a key player in the global market.
No comments:
Post a Comment